Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Leases (2020 - 2026)

InMed Pharmaceuticals has reported Current Leases over the past 5 years, most recently at $408122.0 for Q4 2025.

  • For Q4 2025, Current Leases fell 2.76% year-over-year to $408122.0; the TTM value through Dec 2025 reached $408122.0, down 2.76%, while the annual FY2025 figure was $435507.0, 37.04% up from the prior year.
  • Current Leases for Q4 2025 was $408122.0 at InMed Pharmaceuticals, down from $424765.0 in the prior quarter.
  • Over five years, Current Leases peaked at $435507.0 in Q2 2025 and troughed at $80483.0 in Q2 2021.
  • A 5-year average of $359926.3 and a median of $404163.0 in 2022 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: soared 402.31% in 2022 and later fell 27.5% in 2023.
  • Year by year, Current Leases stood at $391805.0 in 2021, then rose by 5.74% to $414307.0 in 2022, then decreased by 12.1% to $364190.0 in 2023, then grew by 15.25% to $419711.0 in 2024, then dropped by 2.76% to $408122.0 in 2025.
  • Business Quant data shows Current Leases for INM at $408122.0 in Q4 2025, $424765.0 in Q3 2025, and $435507.0 in Q2 2025.